Adrenocot Interactions
There are 823 drugs known to interact with Adrenocot (dexamethasone), along with 23 disease interactions, and 2 alcohol/food interactions. Of the total drug interactions, 166 are major, 601 are moderate, and 56 are minor.
- View all 823 medications that may interact with Adrenocot
- View Adrenocot alcohol/food interactions (2)
- View Adrenocot disease interactions (23)
Most frequently checked interactions
View interaction reports for Adrenocot (dexamethasone) and the medicines listed below.
- Amikin (amikacin)
- Amikin (amikacin)
- AtroPen (atropine)
- AtroPen (atropine)
- Caltrate 600+D (calcium / vitamin d)
- Caltrate 600+D (calcium / vitamin d)
- cefotaxime
- cefotaxime
- dopamine
- dopamine
- Garamycin (gentamicin)
- Garamycin (gentamicin)
- Griseofulvic (griseofulvin)
- Griseofulvic (griseofulvin)
- IBU (ibuprofen)
- IBU (ibuprofen)
- nitazoxanide
- nitazoxanide
- ramipril
- ramipril
- Sronyx (ethinyl estradiol / levonorgestrel)
- Sronyx (ethinyl estradiol / levonorgestrel)
- tizanidine
- tizanidine
- Unasyn (ampicillin / sulbactam)
- Unasyn (ampicillin / sulbactam)
- vancomycin
- vancomycin
- Zanaflex (tizanidine)
- Zanaflex (tizanidine)
Adrenocot alcohol/food interactions
There are 2 alcohol/food interactions with Adrenocot (dexamethasone).
Adrenocot disease interactions
There are 23 disease interactions with Adrenocot (dexamethasone) which include:
- infections
- prematurity
- (+) tuberculin test
- cirrhosis
- depression/psychoses
- diabetes
- electrolyte imbalance
- fluid retention
- GI perforation
- hyperadrenocorticalism
- hyperlipidemia
- hypothyroidism
- liver disease
- MI
- myasthenia gravis
- myopathy
- ocular herpes simplex
- ocular toxicities
- osteoporosis
- PUD
- scleroderma
- strongyloidiasis
- thromboembolism
Report options
More about Adrenocot (dexamethasone)
- Compare alternatives
- Latest FDA alerts (9)
- Side effects
- Dosage information
- During pregnancy
- Drug class: glucocorticoids
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Benlysta
Benlysta is used to treat active systemic lupus erythematosus (SLE) and active lupus nephritis. It ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Entyvio
Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn's disease, reducing ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Nplate
Nplate is used to prevent bleeding episodes in people with chronic immune thrombocytopenic purpura ...
Otezla
Otezla (apremilast) is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers ...
Saphnelo
Saphnelo is used for moderate to severe SLE (lupus) for adults who are also receiving other lupus ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.